Literature DB >> 21702391

Botulinum toxin type A for nonsurgical lateral release in patellofemoral pain syndrome: a case study.

David F Drake1, Peter E Pidcoe, Jeff Ericksen.   

Abstract

SETTING: Outpatient rehabilitation clinic. PATIENT: A 37-year-old physically active male. CASE DESCRIPTION: The patient presented with anterior left knee pain, exacerbated when climbing stairs, sitting, and running. Exam showed lateral tracking patellae and palpable crepitus. One hundred fifty units of botulinum toxin A was injected into his left vastus lateralis. He underwent a 12-week home exercise program targeting the vastus medialis (VM). ASSESSMENT/
RESULTS: Visual analog scale decreased from 70 to 0 on a 150-mm scale, from initial until 8 weeks postinjection. Functional Index Questionnaire increased from 5 to 16 over the same period. Knee torque and surface electromyography findings showed increased activity of the VM during knee extension.
CONCLUSION: Botulinum injection into the vastus lateralis in conjunction with VM strengthening may provide more effective treatment of patellofemoral pain syndrome. Further study is needed to explore this novel treatment of patellofemoral pain syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21702391     DOI: 10.7205/milmed-d-10-00345

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  3 in total

1.  The non-operative treatment of anterior knee pain.

Authors:  Wisam Al-Hakim; Parag Kumar Jaiswal; Wasim Khan; David Johnstone
Journal:  Open Orthop J       Date:  2012-07-27

2.  Botulinum toxin injections as salvage therapy is beneficial for management of patellofemoral pain syndrome.

Authors:  Yuval Kesary; Vivek Singh; Tal Frenkel-Rutenberg; Arie Greenberg; Shmuel Dekel; Ran Schwarzkopf; Nimrod Snir
Journal:  Knee Surg Relat Res       Date:  2021-10-29

Review 3.  The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee Pain.

Authors:  Barbara J Singer; Benjamin I Silbert; Peter L Silbert; Kevin P Singer
Journal:  Toxins (Basel)       Date:  2015-08-25       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.